Pharmaceutical Investing Vertex Announces Northern Ireland Offer Accepted for Cystic Fibrosis Treatments
Health Canada Approves PrSYMDEKO (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis
RETRANSMISSION: Group Eleven to be Featured on Radius Research for a Live Company Pitch, Deep Dive and Q&A Webinar
Freegold Reports Final 2024 Drilling Results from Golden Summit Continuing to Confirm Higher Grade Potential
